| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Eureka Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $130.85M | Series E | 12/16/2019 | $45M | $359.7M | $4.16 | Lyell Immunopharma, Acorn Pacific Ventures, GP Capital, Suma Venture, Harbinger Venture Capital, Yuan Capital, Majuven | ||||
 | Geneoscopy | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $163.58M | Series C | 1/8/2025 | $79.05M | $447.85M | $4.13 | Bio-Rad Laboratories, Petrichor, Labcorp, Morningside Ventures, Lightchain Capital, NT Investments, Granger Management, Mercy Health, Tri Locum Partners | ||||
 | Happy Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $63.16M | Series B-1 | 8/18/2026 | $26.14M | $47.78M | $1.92 | ARCH Venture Partners, OpenLoop | ||||
 | Immune-Onc Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $143.15M | Series B3 | 1/6/2023 | $30M | $262.2M | $2.11 | Triwise Capital, Proxima Ventures | ||||
 | Kyruus | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $192.53M | Series E | 9/15/2022 | $35.1M | $359.84M | $23.40 | Undisclosed Investors | ||||
 | LifeMine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $522.71M | Series E | 8/6/2026 | $150.54M | $469.78M | $0.78 | Milky Way Investments, Bezos Expeditions, Gates Frontier, RA Capital Management, GV, LoLa Capital Partners, GSK, Invus, ARCH Venture Partners | ||||
 | NextPoint | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $196.84M | Series B | 7/30/2026 | $156.21M | $356.79M | $6.00 | Catalio Capital, MPM BioImpact, Leaps by Bayer, Sanofi Ventures, Invus, Sixty Degree Capital, Binney Street Capital, Gordon Freeman, Arkin Capital, WTT Investment, PagodaTree Partners | ||||
 | Proclara Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $112.79M | Series F | 11/7/2018 | $6.92M | $310.98M | $0.90 | Undisclosed Investors | ||||
 | Prosetta Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $63.64M | Series D | 12/31/2015 | $31.1M | $378.68M | $4.50 | Takeda Ventures, Alger | ||||
 | Ratio Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $151.27M | Series C | 7/31/2026 | $70M | $398.34M | $43.69 | Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company, Wasatch Group | ||||
 | Sapience Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $63.88M | Series B | 5/31/2022 | $28.25M | $289.73M | $3.60 | NexPoint, Bristol Myers Squibb, Eshelman Ventures, Kingdon Capital | ||||
 | Scipher Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $238.76M | Series D | 2/24/2022 | $120.72M | $498.65M | $38.12 | Cowen Healthcare Investments, Neuberger Berman, Hitachi Ventures, Laurion Capital, Monashee Investment Management, Northpond Ventures, aMoon, Khosla Ventures, Optum Ventures, Echo Health Ventures, Alumni Ventures | ||||
 | Solera Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $161.62M | Series E-1 | 1/14/2025 | $15M | $173.3M | $1.54 | Health Care Service Corporation, Adams Street, Cobalt Ventures, Horizon Mutual Holdings | ||||
 | Tomorrow Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $92.06M | Series B | 6/29/2022 | $60M | $380.93M | $8.96 | BOND, Andreessen Horowitz, Obvious Ventures, BoxGroup, Sound Ventures | ||||
 | Xalud Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $72.64M | Series C | 8/24/2021 | $32.75M | $259.4M | $2.80 | PBM Capital Group | ||||
 | Aiolos Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $247.55M | Series A | 10/24/2023 | $180M | $436.12M | $1.19 | Atlas Venture, Bain Capital Life Sciences, Forbion, Sofinnova Investments, RA Capital Management | ||||
 | Akili | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $275.08M | Series D | 5/26/2021 | $151.68M | $452.34M | $8.43 | Neuberger Berman Funds, Polaris Partners, Mirae Assets, Shionogi & Co LTD, New Leaf Venture Partners, Dave Baszucki, QUAD Investment Management, Ladera Venture Partners, Temasek, Baillie Gifford, JAZZ Venture Partners, Evidity Health Capital, Omidyar Technology Ventures, Fearless Ventures, Amgen Ventures, M Ventures | ||||
 | Alleviant Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $182.73M | Series 2 | 1/14/2025 | $91.4M | $258.67M | $1.28 | Gilde Healthcare, Omega Funds, S3 Ventures, RiverVest Venture Partners, Vensana Capital, Longview Ventures, Gilmartin Capital, TMC Corporation | ||||
 | Allotera Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $322.92M | Series C | 7/23/2026 | $83.2M | $291.45M | $1.77 | Fidelity, RiverVest Venture Partners, Lightchain Capital, LYZZ Capital, Abingworth, Intermediate Capital Group, Tybourne Capital Management, Aisling Capital Management, BioGenerator Ventures, Sands Capital, Alexandria Venture Investments, Velosity Capital, Falcon Edge Capital | ||||
 | Atsena Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $235.9M | Series C-3 | 4/2/2025 | $60M | $337.46M | $4.13 | Bain Capital, Wellington Management, Lightstone Ventures, Sofinnova Investments, Abingworth, Foundation Fighting Blindness, Hatteras Venture Partners, Osage University Partners, Manning Family Foundation | ||||
 | Elligo Health Research | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $213.37M | Series E-1 | 9/23/2021 | $34.87M | $392.04M | $1.99 | Morgan Stanley Expansion Capital, Ally Bridge Group, Norwest Venture Partners, Cerner, Hatteras Venture Partners, Noro-Moseley Partners, Piper Sandler, Shumway Capital, Syneos Health | ||||
 | Ethyreal Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $150.00K | -- | 1 | Not available | -- | -- | $104.65M | Series B | 6/10/2026 | $60M | $353.63M | $4.43 | Avoro Capital, Atlas Venture, Medicxi Ventures, Nandi Life Sciences, Checkpoint Capital | ||||
 | Evommune | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $268.46M | Series C | 10/31/2024 | $115.5M | $346.35M | $1.59 | RA Capital Management, Sectoral Asset Management, B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund, RTW Investments, ADAR1 Capital Management, NEXTBio Capital, Beiersdorf Venture Capital, FemHealth Ventures, Allostery Investments LP, Pivotal bioVenture Partners, EQT Life Sciences, Andera Partners, Amplitude Ventures, SymBiosis, Verition Fund Management | ||||
 | HealthTap | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $93.45M | Series B | 11/6/2024 | $28.05M | $44.1M | $0.21 | Undisclosed Investors | ||||